Abraxane®
Paclitaxel NAB (nanoparticle albumin-bound) is a chemotherapy agent used for the treatment of breast cancer, non-small cell lung cancer (NSCLC), and pancreatic adenocarcinoma. By binding paclitaxel to albumin nanoparticles, it eliminates the need for toxic solvents, improving delivery to tumor tissue and reducing hypersensitivity reactions.
| Dosage Form | IV Injectable (Lyophilized Powder for Suspension) |
| Strength | 100 mg/vial |
| Storage | Store at 20–25°C. Reconstituted suspension stable for 8 hours at 2–8°C. |
| Category | Oncology |
| Availability | Available for Transfer |
Metastatic breast cancer after failure of combination chemotherapy; locally advanced or metastatic NSCLC; metastatic adenocarcinoma of the pancreas.
Paclitaxel promotes microtubule assembly and stabilizes tubulin polymers, preventing depolymerization. This inhibits the normal dynamic reorganization of the microtubule network required for mitosis and cell proliferation.
Each Burrard Pharmaceuticals technology transfer package for Paclitaxel NAB includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.